Random-controlled Trial of Kechuanning Capsules on Chronic Obstructive Pulmonary Disease Patients
10.3969/j.issn.1005-5304.2014.07.007
- VernacularTitle:咳喘宁胶囊治疗稳定期慢性阻塞性肺疾病随机对照试验
- Author:
Jie SUN
;
Minjuan HAN
;
Xuhui ZHANG
;
Pengpeng CAO
- Publication Type:Journal Article
- Keywords:
Kechuanning capsules;
COPD;
random-controlled trial
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2014;(7):22-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of Kechuanning capsules for the treatment of chronic obstructive pulmonary disease (COPD) in stable phase.Methods Totally 110 patients with stable COPD were randomly divided into the therapy group and the control group, 55 cases in each group. Patients in both groups were given ipratropium bromide solution for inhalation. On the basis of western medicine treatment, the therapy group took Kechuanning capsules orally at the same time, 4 softgels for each time, 3 times a day;on the basis of western medicine treatment, the control group took the same amount of placebo capsules. The treatment lasted three months. Meanwhile, the clinical efficacy, BODE index, CAT score and ADRs of patients in the two groups were observed.Results The clinical efficacy in the therapy group was 96.00% (48/50), and 88.24% (45/51) in the control group, with statistical significance (P<0.05). BODE index and CAT score in the two groups decreased and the therapy group was lower than the control group (P<0.05). Liver and kidney function had no obvious abnormalities in the treatment group before and after treatment.Conclusion Kechuanning capsules can effectively reduce the BODE index and CAT score in patients with stable COPD, improve patients' life quality and clinical outcomes, and no obvious side effect has been found.
